0001193125-22-150966.txt : 20220516 0001193125-22-150966.hdr.sgml : 20220516 20220516083535 ACCESSION NUMBER: 0001193125-22-150966 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220516 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc. CENTRAL INDEX KEY: 0001664106 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471514975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38707 FILM NUMBER: 22925741 BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-245-0399 MAIL ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 8-K 1 d362264d8k.htm 8-K 8-K
false 0001664106 0001664106 2022-05-16 2022-05-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2022

 

 

LOGICBIO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38707   47-1514975

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

65 Hayden Avenue, 2nd Floor

Lexington, MA

   02421
(Address of principal executive offices)   (Zip Code)

(617) 245-0399

(Registrant’s telephone number, including area code)

n/a

(Former name, former address and formal fiscal year, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   LOGC   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On May 16, 2022, LogicBio Therapeutics, Inc. (the “Company”) announced financial results for the quarter ended March 31, 2022 and commented on certain corporate highlights and plans. A copy of the Company’s press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is incorporated herein by reference.

The information in this Report (including Item 2.02 and Exhibit 99.1) is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		   

Exhibit Description

99.1    Press Release issued by LogicBio Therapeutics, Inc. on May 16, 2022.
104    Cover Page Interactive Data File (embedded with Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 16, 2022     LOGICBIO THERAPEUTICS, INC.
    By:  

/s/ Cecilia Jones

    Name:   Cecilia Jones
    Title:   Chief Financial Officer
 EX-99.1 2 d362264dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates

– FDA lifted clinical hold on SUNRISE trial in pediatric patients with methylmalonic acidemia

–Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022

–LogicBio to present at ASGCT 2022 Annual Meeting

LEXINGTON, Mass., May 16, 2022 — LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today reported financial results for the quarter ended March 31, 2022, and highlighted recent business updates.

“Earlier this month, we were pleased to announce that the FDA lifted the clinical hold on our LB-001 IND, allowing us to resume dosing of our SUNRISE trial,” said Frederic Chereau, president and chief executive officer of LogicBio. “We are also excited to see the progression of our GeneRide® platform as well as advancements from our CMC team, including our proprietary mAAVRxTM system, which is a transfection process optimized to improve manufacturing yields and product quality. Finally, we continue to progress well with our Daiichi Sankyo and CANbridge collaborations.”

Recent Business Highlights:

 

  •  

In May, LogicBio announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the company’s LB-001 Investigational New Drug Application (IND), allowing patient dosing to resume in the Phase 1/2 SUNRISE trial in pediatric patients with methylmalonic acidemia. The company expects to dose the next patient in the SUNRISE trial in the third quarter of 2022. Following the lifting of the clinical hold, the company announced that it reinstated its previous guidance and expects to present interim clinical data from the SUNRISE trial by the end of the second quarter of 2022.

 

  •  

In May, LogicBio announced that it will present at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, to be held May 16-19, 2022. The two oral and two poster presentations highlight the company’s GeneRide technology in preclinical hereditary tyrosinemia type 1 models and optimized adeno-associated virus manufacturing processes.

First Quarter 2022 Financial Results:

Three Months Ended March 31, 2022 and 2021

 

  •  

Revenue: Revenue for the quarter ended March 31, 2022 consisted of $2.8 million in collaboration and service revenue recognized under our April 2021 agreements with CANbridge Care Pharma Hong Kong Limited (CANbridge) and Daiichi Sankyo Company, Limited (Daiichi Sankyo). Revenue for the quarter ended March 31, 2021 was $0.5 million consisting solely of service revenue recognized under our January 2020 agreement with Takeda Pharmaceutical Company Limited (Takeda). The agreement with Takeda expired by its own terms in the year ended December 31, 2021.

 

  •  

R&D Expenses: Research and development expenses for the quarter ended March 31, 2022 were $5.6 million, compared to $6.4 million for the quarter ended March 31, 2021. The decrease of approximately $0.8 million was primarily due to a decrease of $0.9 million related to LB-001 external development and manufacturing costs incurred during first quarter 2021 to start up the LB-001 SUNRISE clinical trial and manufacture appropriate clinical supply that did not re-occur during the first quarter of 2022.

 

  •  

G&A Expenses: General and administrative expenses were $3.6 million for the quarter ended March 31, 2022, compared to $4.1 million for the quarter ended March 31, 2021. The decrease of approximately $0.4 million was primarily driven by a decrease of approximately $0.6 million in professional service fees as we brought more professional work in-house through key hires made during 2021. As such, personnel expenses increased approximately $0.3 million as we filled key open positions within the human resources, legal and business development functions.

 

  •  

Net Loss: Net loss for the quarter ended March 31, 2022 was $6.7 million or $0.20 per share, compared to a net loss of $10.3 million, or $0.32 per share, for the quarter ended March 31, 2021.

 

  •  

Cash Position: As of March 31, 2022, we had cash and cash equivalents of $42.7 million as compared to $53.5 million as of December 31, 2021. As of March 31, 2022, we had 32,962,733 shares outstanding.

 

  •  

Financial Guidance: Based upon our current operating plan, we believe that our $42.7 million in cash and cash equivalents as of March 31, 2022 will enable us to fund our operating expenses and capital expenditure requirements through the first quarter of 2023.

About LogicBio Therapeutics

LogicBio® Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company’s genome editing platform, GeneRide®, is a new approach to precise gene insertion harnessing a cell’s natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company’s gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company’s proprietary system, mAAVRx™, aims to overcome one of the current limitations of AAV manufacturing by optimizing the transfection process to improve yields and product quality. The company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

About the SUNRISE Trial

The SUNRISE trial is an open-label, multi-center, Phase 1/2 clinical trial designed to assess the safety, tolerability and preliminary efficacy of a single intravenous infusion of LB-001 in pediatric patients with methylmalonic acidemia (MMA) characterized by methylmalonyl-CoA mutase gene (MMUT) mutations. With the aim of evaluating LB-001 at an early age, the SUNRISE trial is designed to enroll patients with ages ranging from six months to twelve years and evaluate a single administration of LB-001 at two dose levels (5 x 1013 vg/kg and 1 x 1014 vg/kg) with dose escalation subject to certain conditions.

About LB-001

LB-001 is an investigational, first-in-class, single-administration, genome editing therapy for early intervention in methylmalonic acidemia (MMA) using LogicBio’s proprietary GeneRide® drug development platform. GeneRide technology utilizes a natural DNA repair process called homologous recombination that enables precise editing of the genome without the need for exogenous nucleases and promoters that have been associated with an increased risk of immune response and cancer. LB-001 is designed to non-disruptively insert a corrective copy of the methylmalonyl-CoA mutase (MMUT) gene into the albumin locus to drive lifelong therapeutic levels of MMUT expression in the liver, the main site of MMUT expression and activity. LB-001 is delivered to hepatocytes intravenously via liver-targeted, engineered recombinant adeno-associated virus vector (rAAV-LK03). Preclinical studies found that LB-001 was safe and demonstrated transduction of hepatocytes, site-specific genomic integration, and transgene expression. LB-001–corrected hepatocytes in a mouse model of MMA demonstrated preferential survival and expansion (selective advantage), thus contributing to a progressive increase in hepatic MMUT expression over time. LB-001 resulted in improved growth, metabolic stability, and survival in MMA mice. The U.S. Food and Drug Administration (FDA) granted fast track designation, rare pediatric disease designation and orphan drug designation for LB-001 for the treatment of MMA. In addition, the European Medicines Agency (EMA) granted orphan drug designation for LB-001 for the treatment of MMA.

About Methylmalonic Acidemia (MMA)

Methylmalonic acidemia (MMA) is a rare and life-threatening genetic disorder affecting approximately 1 in 50,000 newborns in the United States. In the most common form of MMA, a mutation in a gene called methylmalonyl-CoA mutase (MMUT) prevents the body from properly processing certain fats and proteins. As a result, toxic metabolites accumulate in the liver, in muscle tissue and in the brain. Symptoms include vomiting, lethargy, seizures, developmental delays and organ damage. There is no approved medical therapy addressing the underlying cause of the disease. To manage the symptoms, patients go on a severely restrictive, low-protein, high-calorie diet, often through a feeding tube. Even with aggressive management, these patients often experience life-threatening metabolic crises that can require recurrent hospitalizations and cause permanent neurocognitive damage. Because of this risk for irreversible damage, early intervention is critical, and newborns are screened for MMA in every state in the United States.

Forward-Looking Statements

Statements in this press release regarding LogicBio’s strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, including but not limited to statements regarding resumption of dosing in LogicBio’s SUNRISE clinical trial and timing thereof; the improvement of manufacturing yields and product quality; our expectations to continue enrollment and dosing of clinical trial subjects; our expectations on the continuation of our current collaborations; the potential of the GeneRide® platform; and the anticipated timing of announcing interim clinical data. The terms “anticipate,” “progress,” “expects to,” “designed,” “evaluate,” “aim,” “enables,” “continue,” “potential” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the risk that we will need to obtain the approval of each clinical trial site’s institutional review board prior to resuming enrollment of our SUNRISE trial; we may encounter difficulties enrolling patients; we may encounter difficulties or delays with respect to our collaborations; the potential direct or indirect impact of the COVID-19 pandemic on our business, operations, and the markets and communities in which we and our partners, collaborators and vendors operate; manufacturing risks; risks associated with management and key personnel changes and transitional periods; the actual funding required to develop and commercialize product candidates, including for safety, tolerability, enrollment, manufacturing or economic reasons; the timing and content of decisions made by regulatory authorities; the actual time it takes to initiate and complete preclinical and clinical studies; the competitive landscape; changes in the economic and financial conditions of LogicBio; and LogicBio’s ability to obtain, maintain and enforce patent and other intellectual property protection for LB-001 and any other product candidates. Other risks and uncertainties include those identified under the heading “Risk Factors” in LogicBio’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and LogicBio does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.

LogicBio Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

 

     Three Months Ended March 31,  
     2022     2021  

REVENUE

     

Collaboration and service revenue

    $ 2,816     $ 461  
  

 

 

    

 

 

  

Total revenue

      2,816       461  

OPERATING EXPENSES

     

Research and development

      5,641       6,419  

General and administrative

      3,624       4,059  
  

 

 

    

 

 

  

Total operating expenses

      9,265       10,478  
  

 

 

    

 

 

  

LOSS FROM OPERATIONS

      (6,449 )      (10,017 ) 
  

 

 

    

 

 

  

OTHER INCOME (EXPENSE):

     

Interest income

      5       6  

Interest expense

      (218 )      (271 ) 
  

 

 

    

 

 

  

Total other expense, net

      (213 )      (265 ) 
  

 

 

    

 

 

  

Net loss

    $ (6,662 )    $ (10,282 ) 
  

 

 

    

 

 

  

Net loss per share—basic and diluted

    $ (0.20 )    $ (0.32 ) 
  

 

 

    

 

 

  

Weighted-average common stock outstanding—basic and diluted

      32,961,180       31,933,794  
  

 

 

    

 

 

  

LogicBio Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

 

     As of  
     March 31,
2022		      December 31,
2021		  
     (Unaudited)  

Cash and cash equivalents

    $ 42,739      $ 53,480  

Other assets

      9,160        9,290  
  

 

 

     

 

 

  

TOTAL ASSETS

    $ 51,899      $ 62,770  
  

 

 

     

 

 

  

Accounts payable, accrued expenses and other liabilities

    $ 26,988      $ 32,043  

Stockholders’ equity

      24,911        30,727  
  

 

 

     

 

 

  

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

    $ 51,899      $ 62,770  
  

 

 

     

 

 

  

Investor Contact:

Stephen Jasper

Gilmartin Group

(858) 525-2047

stephen@gilmartinir.com

Media Contact:

Adam Daley

Berry & Company Public Relations

W:212-253-8881

C: 614-580-2048

adaley@berrypr.com

EX-101.SCH 3 logc-20220516.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 logc-20220516_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 logc-20220516_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g362264g0513230954994.jpg GRAPHIC begin 644 g362264g0513230954994.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 16, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001664106
Document Type 8-K
Document Period End Date May 16, 2022
Entity Registrant Name LOGICBIO THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38707
Entity Tax Identification Number 47-1514975
Entity Address, Address Line One 65 Hayden Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Lexington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02421
City Area Code (617)
Local Phone Number 245-0399
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol LOGC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
XML 8 d362264d8k_htm.xml IDEA: XBRL DOCUMENT 0001664106 2022-05-16 2022-05-16 false 0001664106 8-K 2022-05-16 LOGICBIO THERAPEUTICS, INC. DE 001-38707 47-1514975 65 Hayden Avenue 2nd Floor Lexington MA 02421 (617) 245-0399 false false false false Common Stock, par value $0.0001 per share LOGC NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '!$L%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !P1+!4P)8&)^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*'%H#R;UI:.G#@8K;.QF;+4UBV-C:R1]^SE9FS*V!]C1TN]/ MGT"M#D+[B,_1!XQD,3V,KNN3T&'#SD1! "1]1J=2F1-];AY]=(KR,YX@*/VA M3@B\JM;@D)11I& "%F$A,MD:+71$13Y>\48O^/ 9NQEF-&"'#GM*4)Q:^$.F&"$T:7O IJ%.%?_Q,X=8-?DF.R2&H:A')HYEW>HX>UI_S*O6]@^ MD>HUYE_)"KH$W+#;Y-=F^WC8,621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M '!$L%36'<*P&PO=V]R:W-H965T&UL MG9A=;^(X%(:O9W^%A?9B5VJ;V.6C'5$DFM(IFGZPA=F1=K47)C%@-8DSCL/' MO]_CA"9,-YR@O8$XQ&^>PXJ;\2$4\O M5")B^&6A=,0--/7221,M>)!WBD*'N6[7B;B,6X-^?F^B!WV5F5#&8J))FD41 MU[M;$:K-38NVWF^\RN7*V!O.H)_PI9@*\RV9:&@YI4H@(Q&G4L5$B\5-:T@_ MW[*N[9 _\:<4F_3@FMA0YDJ]V<8XN&FYEDB$PC=6@L/76G@B#*T2NJ10*QX%EH7M7F0>P#ZE@]7X5I_DDV MQ;-MMT7\+#4JVG<&@DC&Q3??[A-QV($=Z<#V'5C.7;PHI[SCA@_Z6FV(MD^# MFKW(0\U[ YR,[:A,C89?)?0S@SOE9Y!D0W@"MX4@.R+XQ'>$=L\(9E+MH](#B'>((_Y/N3+N@CQ_@L>I@+A:)<<;51GGVT/2#0/(>N!V)*O M8E='A"NYKDN[W39UNPA6I\3JH&)E1 M1J_#R>C;;.Q-S\CXV;M **]*RJM3*,>QKW2B=#Z9R=1 "HFG,J@X*#P5U&+C MPGY>AH(\9]%(R]Q[5 V2'8[ MY('O(%PR7(LXPTR-5H9-V?_GG&U4+2 M:(.O*Q^R,EFI&/.V!A'6[IR[E]?7&%&U%%#2A[4\N$H3#ZOLG^%>/=$B3X^ &59L?F"/ M"!O/E\6B?OP:]!K)*MMGN$?_AVR1J!6"X9<\T#VSI M37?17-467H, [-T\C*2R>X9;A].[X1\84^7S["2? M'T5"+VV6OH""6=DB3'A<>SII$#0:W5JPRN49;M+O9%L"(QBG,M^?%2>$6BQ< M[1B6QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD M:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N M0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!I MGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87 M$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%> M* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^ MRPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/- M-;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/ M)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#] M! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q M P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL M0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ <$2P5)>*NQS M $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/ M:(7->=I3W;+T]!;X"O M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_ M'FR-9V87YTC'?8Q' M]>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X3[+O,&@EXN1 M:T/9=1,92L88!.R '<(Y_A^[<#K3P&]'@!6^AC(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R! M+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E< M)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-: M"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$% M @ <$2P5"0>FZ*M ^ $ !H !X;"]? M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2 M*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+B MRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L# M!!0 ( '!$L%1ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM M;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL M>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE M@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J M1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/; M&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G= M560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( '!$L%36'<*P&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !P1+!499!Y MDAD! #/ P $P @ ',$@ 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 "0 ) #X" 6% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d362264d8k.htm d362264dex991.htm logc-20220516.xsd logc-20220516_lab.xml logc-20220516_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d362264d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d362264d8k.htm" ] }, "labelLink": { "local": [ "logc-20220516_lab.xml" ] }, "presentationLink": { "local": [ "logc-20220516_pre.xml" ] }, "schema": { "local": [ "logc-20220516.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "logc", "nsuri": "http://www.logicbio.com/20220516", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d362264d8k.htm", "contextRef": "duration_2022-05-16_to_2022-05-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d362264d8k.htm", "contextRef": "duration_2022-05-16_to_2022-05-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.logicbio.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001193125-22-150966-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-150966-xbrl.zip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end